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A B S T R A C T
Red blood cell osmotic resistance (RBCOR) is defined as resistance to osmotic chan-
ges in cell integrity after their exposure to hypotonic saline solution. The investigation
examined the effect of rHuEPO on RBCOR in hemodialysed patients. The study included
58 patients aged 49±14 years, treated by hemodialysis for 59±43 months on average.
Half of the patients received rHuEPO for anemia correction. RBCOR was determined in
all patients as 3 values: hemolysis start point (HSP), hemolysis end point (HEP) and
middle osmotic resistance (MOR). The patients underwent laboratory checkup for para-
meters characteristically changed in the uremic syndrome. In the control group of heal-
thy subjects (n=16) RBCOR was only determined. No differences were found in the aver-
age values of HSP, HEP and MOR between the rHuEPO treated group of patinets and
the untreated group. Compared to healthy individuals, the hemodialysed patients dis-
played significantly higher values of HSP, HEP and MOR. The only one significant cor-
relation of RBCOR and routine laboratory features was found between MOR and pre-
dialytic serum concentrations of calcium (r=0.28, p<0.05) and hydrogen ions (r=0.37,
p<0.05). Our results suggest that the administration of rHuEPO does not affect RBCOR
in hemodialysed patients, that RBCOR is not always reduced in this population and
that it correlates with a small number of laboratory parameters characteristic for the
uremic syndrome.
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Introduction
Red blood cell osmotic resistance
(RBCOR) is an in vitro property of eryth-
rocytes to retain their integrity by resis-
ting the osmotic pressure that drives wa-
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ter into the cell when exposed to hypoto-
nic saline solutions. The in vivo role of
hypotonic saline solutions is taken over
by plasma, although it is not hypotonic.
Both in vivo and in vitro, this property
depends on the medium surrounding the
RBC, as well as on the cell membrane fea-
tures. End-stage renal disease (ESRD)
patients tend to have reduced RBCOR,
but it is not a rule1–9. Together with a re-
duced ability of RBC to change their form
while passing through nutritive capilla-
ries10 whose diameters are lower than
those of the RBC11, i.e. with diminished
deformability, it reduces RBC life span
and leads to anemia.
On average, the life span of RBC in
ESRD patients is only half of that in heal-
thy individuals12. This characteristic, how-
ever, may be a contributing, but not the
sole factor responsible for anemia, a com-
mon finding in patients with chronic re-
nal failure (CRF)13. Anemia usually beco-
mes manifest at creatinine clearance
level below 40 ml/min/ 1.73 m2 of body
surface and is aggravated with further
deterioration of renal function14. Although
the level of anemia may vary considerably
in patients at the same stage of renal fail-
ure, it is believed that primary renal disea-
se, with the exception of autosomal domi-
nant polycystic kidney disease (ADPKD),
does not determine the occurrence of ane-
mia15. The cause of anemia is ascribed to
several mechanisms. Those mechanisms
either inhibit RBC production (decreased
erythropoietin production16, iron, folic acid,
vitamin B12 and L-carnitine deficiency4,17,
secondary hyperparathyroidism18–19, cir-
culating uremic erythropoiesis inhibi-
tors20–25 and aluminum toxicity26), or, as
it is already mentioned, shorten the RBC
life span (hemolysis3,27, hypersplenism28).
By far the most important factor is the
erythropoietin shortage4,16,29–33.
The commonly used term for RBCOR
is RBC osmotic fragility (RBCOF). High
osmotic resistance denotes low osmotic
fragility and vice versa.
Forty years ago it was believed that
RBCOR was only affected by uremic plas-
ma, because it was found that the RBC of
uremic individuals had normal life span
after being transfused into healthy per-
sons, whereas the RBC of normal individ-
uals had shortened life span after being
transfused into uremic patients34–36. It
was thought that uremic plasma inhibi-
ted the activity of Na-K pump of RBC37,
which, together with membrane lipids,
retained their biconcave shape and pro-
tected them from hemolysis3. Cheng et
al38 found that the number of these pumps
was lower at the RBC surface in uremic
patients compared to healthy persons.
Dialysis regulates RBCOR by removing
uremic toxins of low molecular mass, re-
ducing serum parathyroid hormone con-
centration, reducing calcium influx into
RBC39, decreasing plasma osmolality2
and increasing RBC fluidity10,40. Recent
studies have demonstrated that RBCOR
in CRF may also be affected through the
RBC membrane metabolism by adminis-
tering antioxidant substances like vita-
min E41–42, vitamin C and zinc43, and cor-
recting serum L-carnitine level1,4–6. The
results of the studies that investigate the
effects of rHuEPO on RBCOR in CRF are
not concordant: they either show no influ-
ence of rHuEPO on RBCOR in this popu-
lation5 or they demonstrate an improve-
ment of RBCOR44–45 under rHuEPO.
This paper attempts to evaluate the
effect of rHuEPO on RBCOR, the frequen-
cy of reduced RBCOR in the population of
ESRD patients treated with HD, and the
correlation with laboratory parameters
characteristic for an abnormal in uremic
syndrome.
Patients and Methods
The study included 58 ESRD patients
(29 women and 29 men), aged between 20
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to 70 years (49±14 years in average),
treated with bicarbonate HD for 59±43
months on average (range 9–176 mon-
ths), three times a week for 4–4.5 hours
using dialyzers made of modified cellulo-
se acetate or diacetate (n=51), or of po-
lysulphone (n=7), with surface area of
1.3–1.7 m2, with blood flow of 250–300
ml/min and dialysate flow of 500 ml/min.
All dialyzers were sterilized with ethyl
oxide. The water for dialysis was prepa-
red with reversed osmosis. Conductivity
below 10 µS/cm was ensured. The micro-
biological quality of water for dialysis and
of dialysate was determined twice mon-
thly.
Half of the patients received rHuEPO
for anemia correction for more than six
months. Twelve of the 29 patients that re-
ceived rHuEPO and 11 of the 29 patients
without rHuEPO, were treated with cal-
cium channel blockers. Patients with au-
toimmune diseases, patients with hemo-
lytic anemia and patients transfused in
the last 3 months were excluded. The con-
trol group consisted of 16 employers of
the dialytic center.
CRF was the consequence of chronic
glomerulonephritis in 31 patients (53.45%),
diabetes mellitus in 8 (13.79%), chronic
interstitial nephritis in 9 (15.52%), arte-
rial hyper-tension in 4 (6.89%), ADPKD
in 3 (5.17%), and of other kidney diseases
in 3 patients (5.17%).
RBCOR was measured using a spec-
trophotometric technique (Dacie and Le-
wis46), whereas the RBC count, hemoglobin
concentration, hematocrit, reticulocyte
proportion, mean corpuscular volume
(MCV) were determined for each patient
with the automatic cell counter (Coulter
Counter). Each patient also underwent
determination of serum iron con-centra-
tion (women 8–30 µmol/l, men 11–32
µmol/l), using a photocolorimetric method
with 2,4,6-three(2-pyridyl)-5-threeazine,
TIBC (50–72 µmol) using a magnesium-
hydro-xicarbonate method, serum urea
concentration (3.40–8.00 mmol/l) using
an enzymatic UV method with urease
and glutamate dehydrogenase, creatinine
(42–115 µmol/l) using an enzymatic colo-
rimetric PAP procedure, potassium (3,6–
5,6 mmol/l) using a flaming spectrophoto-
metry, calcium (2.25–2.75 mmol/l) using
colorimetry with ortocresolphtalein, phos-
phates (0.80–1.40 mmol/l) using a molib-
date UV method, alkaline phosphatase
(women 40–110 U/L, men 43–88 U/l) using
IFCC recommended method with AMP
buffer, arterial acidbase state, bilirubin
(4–20 µmol/l) by DPD method with 2.5
diclorphenildiazonim, i-PTH (8–76 pg/ml)
(ELSA PTH, immunoradiometric assay,
GIF-SUR-YVETTE CEDEX, France) and
plasma osmolality (plasma osmolality
(mmol/l) = 2 × (serum sodium concentra-
tion + serum potassium concentration) +
serum urea concentration + serum gluco-
se concentration (mmol/l)47. Control sub-
jects underwent RBCOR determination
only.
For each patient and control subject
saline solution concentrations were de-
termined from the RBCOR test at three 3
values: hemolysis start point (HSP) – sa-
line solution concentration at the moment
of starting hemolysis, hemolysis end point
(HEP) – saline solution concentration at
the moment of terminating hemolysis,
and middle osmotic resistance (MOR) –
saline solution concentration needed for
the lysis of 50% of RBC) (normal values
are in the Table 1). Lower RBCOR is cha-
racterized by higher HSP, HEP and MOR
values.
The obtained results expressed as ari-
thmetic mean values, standard deviations
and as frequencies were analyzed using a
t-test and a Chi-square test, whereas in-
dividual values were analyzed with a cor-
relation test. Statistical significance was
assessed at the level of 1 and 5% (p<0.01,
p<0.05)48.
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Results
In the group of 58 hemodialysed pa-
tients 50% of RBC lysed (MOR) at saline
concentration of 0.44±0.07%. HSP was
recorded at saline concentration of 0.52±
0.09%, and HEP at 0.31±0.05%. Mean
MOR, HSP and HEP values in the hemo-
dialysed patients were significantly hig-
her than in the healthy control individu-
als (MOR: 0.44±0.07% : 0.37±0.02%; t=
6.69, p<0.01; HSP: 0.52±0.09% : 0.44±
0.02%; t=6.23, p<0.01; HEP: 0.31±0.05% :
0.28±0.02%; t=3.64, p<0.01) (Table 2).
Moreover, 22 of the 58 patients (37.93%)
had normal MOR values, 17 had normal
HSP values (29.31%) and 19 normal HEP
values (32.76%). Correlation tests revea-
led only a statistically significant positive
correlation between MOR and predialysis
serum calcium concentrations (r=0.275,
p<0.05) and hydrogen serum concentra-
tions (r=0.372, p<0.01).
There was no difference in the mean
MOR, HSP and HEP values in the pa-
tients receiving rHuEPO and in the pa-
tients without the rHuEPO treatment
(Table 3). According to the Chi-square
test, among the rHuEPO treated patients
the number of those with normal values
of MOR (12/29:10/29), HSP (9/29:8/29)
and HEP (9/29:10/29) was not statistical-
ly higher compared to non-rHuEPO trea-
ted patients (Table 4). Statistically, the
rHuEPO treated patients were significan-
tly younger in comparison with patients
without rHuEPO treatment, had higher
hematocrit values, more severe acidosis
and higher urea and potassium predia-
lysis serum concentrations. (Table 3).
At almost identical saline concentra-
tions were needed for hemolysis of 50% of
RBC in HD patients (0.44±0.07%) and for
starting hemolysis in healthy control sub-
jects (0.44±0.02%). Moreover, the range
from initial to complete hemolysis in HD
patients was significantly higher (0.31±
0.07%) than in control healthy individua-
ls (0.14±0.02%) (t=2.34, p<0.05).
Discussion
Absolute or relative erythropoietin de-
pletion is considered to be the most im-
portant factor responsible for the occur-
rence of anemia that accompanies
ESRD4,16,29–33. The other factors, such as
a reduced RBCOR and the related RBC
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TABLE 2
RED BLOOD CELL OSMOTIC RESISTANCE (RBCOR) HEMODIALYSIS TREATED PATIENTS




individuals (N=16) t-test signific.
MOR (%NaCl) 0.44±0.07 0.37±0.02 6.69 **s
HSP (% NaCl) 0.52±0.09 0.44±0.02 6.23 **s
HEP (%NaCl) 0.31±0.05 0.28±0.02 3.64 **s
p<0.05; **p<0.01
MOR – middle osmotic resistance, HSP – hemolysis start point, HEP – hemolysis end point
TABLE 1
NORMAL VALUES OF RED BLOOD CELL
OSMOTIC RESISTANCE (RBCOR)











life span are only contributing ele-
ments1–9. Yet, despite their position, they
are the subject of intensive studies.
In our study we have attempted to es-
tablish a potential link between rHuEPO
treatment and RBCOR. This is not the
first attempt of the kind. However, pre-
vious researchers have not obtained iden-
tical results.
In 1991, Icardi et al.44 investigated the
effects of rHuEPO treatment on RBC me-
chanic fragility and deformability in HD
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TABLE 3
CHARACTERISTICS OF HEMODIALYSIS TREATED PATIENTS AFTER GROUPING ACCORDING
TO rHuEPO TREATMENT
With rHuEPO Without rHuEPO t-test signific.
Number of patients 29 29
MOR (%NaCl) 0.44±0.05 0.45±0.08 0.57 ns
HSP (% NaCl) 0.50±0.07 0.53±0.09 1.42 ns
HEP (%NaCl) 0.31±0.06 0.31±0.05 0.41 ns
Age (years) 42.48±12.97 55.91±11.92 4.11 **s
HD treatment (months) 61.78±46.63 56.50±40.74 0.46 ns
Urea (mmol/l) 28.61±5.29 25.63±5.74 2.07 **s
Creatinine (µmol/l) 1009.66±235.25 941.00±199.49 1.19 ns
Potassium (mmol/l) 5.99±0.92 5.51±0.88 2.03 *s
Calcium (mmol/l) 2.46±0.18 2.51±0.18 1.06 ns
Bilirubin (µmol/l) 12.45±5.74 13.25±6.23 0.51 ns
Iron (µmol/l) 11.24±3.28 10.81±2.87 0.53 ns
Hematocrit (l/l) 0.34±0.04 0.27±0.04 6.67 **s
Reticulocytes (x 103 E) 11.83±8.55 13.48±4.87 0.90 ns
i-PTH (pg/ml) 213.20±230.67 238.02±233.82 0.41 ns
* p<0.05; **p<0.01, ns – not significant
MOR – middle osmotic resistance, HSP – hemolysis start point, HEP – hemolysis end point
TABLE 4
FREQUENCY OF NORMAL RED BLOOD CELL OSMOTIC RESISTANCE (RBCOR) PARAMETERS IN
HEMODIALYSIS TREATED PATIENTS AFTER GROUPING ACCORDING TO rHuEPO TREATMENT
Parameter







MOR 12 10 0.07 ns
HSP 9 8 0.00 ns
HEP 9 10 0.00 ns
Number of patients treated
with calcium antagonists
12 11 0.01 ns
ns – not significant
MOR – middle osmotic resistance, HSP – hemolysis start point, HEP – hemolysis end point
and hemodiafiltration patients. In their
study, both groups of patients, particular-
ly the HD patients, showed RBC mem-
brane damage. They found that rHuEPO
considerably improved the studied prop-
erties, which they attributed to the pro-
duction of new RBC. Three years later, in
their study of the effects of rHuEPO treat-
ment on the cardiovascular function, Hae-
dersdal et al.45 recorded a reduced RBCOR
in a small HD treated group (n= 11) (al-
though it was not possible to conclude
from the results presented in the their ta-
ble). They concluded that the unchanged
peripheral vascular resistance, blood pres-
sure and cardiac index were due to a re-
duced RBCOR, i.e. to its higher flexibility
despite increased hemoglobin, hematocrit
and RBC volume.
In 1995 Labonia4 found that the sub-
stitution of L-carnitine maintained the
same hematocrite level at considerably
lower rHuEPO dosages in 13 hemodia-
lysed patients with no change in RBCOR
and endogenous erythropoietin concen-
tration. The reduced rHuEPO dosage yiel-
ded the same effect only in patients recei-
ving higher (although statistically not
significant) initial rHuEPO dosages (120.3±
51.3 : 81.2±40.4 UI/kg body weight week-
ly) and having a higher (also not signifi-
cantly) endogenous erythropoietin level
(38.6±11.8 : 26.8±7.0 mU/ml). He conclu-
ded that erythropoietin resistance was
due to L-carnitine deficiency.
In their examination of the relation-
ship between serum L-carnitine and
RBCOF in HD patients, Matsumara et
al3. found no difference in RBCOF in
rHuEPO treated patients and non-rHuE-
PO treated patients. They concluded that
rHuEPO neither directly affected RBCOF,
nor the related newly produced RBC.
San et al.49 found that rHuEPO impro-
ved lipid peroxidation and intraerythro-
cytic antioxidative system, and that ane-
mia correction was partly due to RBC
membrane stability enhancement.
Our results are in agreement with the
previous results of only several of the
mentioned authors3,4. Namely, we were
not able to prove that rHuEPO affected
RBCOR either. The results meet our ex-
pectations because rHuEPO neither chan-
ges uremic plasma, nor do the rHuEPO-
related RBC differ from those produced
by endogenous erythropoietin.
ESRD patients do not necessarily ex-
hibit a reduced RBCOR. Of our patients,
normal MOR was found in 37.93% cases,
normal HSP was detected in 29.31% ca-
ses and normal HEPwas found in 32.76%
cases. However, all the three parameters
were normal in only 5 patients (8.62%).
Docci et al.7 found a normal RBCOR in
every fifth respondent, Weiner et al8. in
each, and Jakic et al.9 in 87.72% of the
patients.
More than 15 years ago, secondary
hyperparathyroidism and parathormone
were given high importance in the pat-
hophysiology of anemia in CRF patients.
Parathormone was proved to be a direct
and indirect erythrocytopoiesis inhibitor,
to reduce RBCOR and to shorten RBC life
span7–8,50–52. Our study found no correla-
tion between i-PTH and RBCOR, but a
statistically significant correlation was
established between MOR and serum
concentrations of calcium and hydrogen
ions. Docci et al7. did not find any correla-
tion between RBCOR and histochemical
indicators of secondary hyperparathyroi-
dism. Matsumara et al.3 did not find a
correlation between RBCOR and serum
concentrations of urea and creatinine,
but only with the serum L-carnitine level.
Wu et al.2 presented a correlation be-
tween RBCOF and serum urea, parathor-
mone and osmolality.
Based on the obtained results we con-
clude that rHuEPO does not affect on
RBCOR in hemodialysed patients, that
not all hemodialysed patients display a
reduced RBCOR, and that the low num-
ber of statistically significant correlations
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between RBCOR and laboratory parame-
ters characteristic abnormal in uremic
syndrome (with serum calcium and hy-
drogen concentrations) do not indicate
with certainty their causal relationship.
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UTJECAJ LIJE^ENJA ERITROPOETINOM (rHuEPO) NA OSMOTSKU
REZISTENCIJU ERITROCITA
S A @ E T A K
U bolesnika s kroni~nim bubre`nim zatajenjem (KBZ) osmotska rezistencija eritro-
cita (ORE), sposobnost da zadr`e svoj integritet, opiru}i se osmozi, pri izlaganju hipoto-
ni~nim otopinama natrijeva klorida, smanjena je ~esto, ali ne uvijek. Zajedno sa sma-
njenom sposobnosti eritrocita da mijenjanju svoj oblik pri prolasku kroz nutritivne
kapilare, dovodi do skra}enja njihovog vijeka, a tako i do nastanka anemije. Iako se
vjeruje da vijek eritrocita ove skupine bolesnika uglavnom odre|uju izvaneritrocitni
~imbenici i sami eritrociti su ~esto predmet prou~avanja. U ovom radu ispitivali smo da
li humani rekombinantni eritropoetin (rHuEPO) utje~e na ORE hemodijalizom lije~e-
nih bolesnika. Ispitivanjem je obuhva}eno 58 bolesnika, prosje~ne dobi 49±14 godina,
prosje~no lije~enih hemodijalizom 59±43 mjeseca. Polovica bolesnika je za korekciju
anemije dobivala rHuEPO. Svakom bolesniku odre|ena je ORE (koncentracija natrijeva
klorida kod koje je zabilje`ena po~etna – HSP i zavr{na hemoliza – HEP i koncentracija
natrijeva klorida kod koje je hemoliziralo 50 % eritrocita – MOR) i niz laboratorijskih
parametara karakteristi~nih za uremijski sindrom. Kontrolnim zdravim ispitanicima
(n=16) odre|ena je samo ORE. Prosje~ne vrijednosti HSP, HEP i MOR bolesnika lije~e-
nih i nelije~enih rHuEPOm nisu se razlikovale. Bolesnici lije~eni hemodijalizom imali
su od kontrolnih ispitanika statisti~ki zna~ajno ni`e prosje~ne vrijednosti HSP, HEP i
MOR. Na|ena je samo pozitivna zna~ajna korelacija MOR s predijaliznom razinom
kalcija (r=0,28, p<0,05) i vodikovih iona (r=0,37, p<0,05). Na osnovi rezultata na{eg is-
pitivanja zaklju~ujemo da rHuEPO ne utje~e na ORE hemodijalizom lije~enih bolesni-
ka, da smanjena ORE nije obvezan nalaz i da je u korelaciji s malim brojem laboratorij-
skih parametara karakteristi~nih za uremijski sindrom.
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